Follow-Up Has Improved for AMI, Heart Failure Hospitalization

Follow Drugslib on

Medically reviewed by Drugs.com.

By Elana Gotkine HealthDay Reporter

MONDAY, Aug. 5, 2024 -- Follow-up has improved for patients with acute myocardial infarction (AMI) and heart failure, but disparities persist in follow-up rates, according to a study published online Aug. 6 in the Annals of Internal Medicine.

Timothy S. Anderson, M.D., from the University of Pittsburgh, and colleagues describe trends and disparities in follow-up after AMI and heart failure hospitalizations in a retrospective cohort study. Data were included for 1,678,088 AMI and 4,245,665 heart failure hospitalizations.

The researchers found that from 2010 to 2019, there was an increase in the cardiology follow-up rate, from 48.3 to 61.4 percent for AMI hospitalizations and from 35.2 to 48.3 percent for heart failure hospitalizations. Follow-up rates increased for all subgroups for both conditions, but there was a worsening of disparities seen for Hispanic patients with AMI and for heart failure patients who were Asian, Black, Hispanic, Medicaid dual-eligible, and residents of counties with higher levels of social deprivation. The largest disparities by 2019 were between Black and White patients (51.9 versus 59.8 percent for AMI; 39.8 versus 48.7 percent for heart failure) and for Medicaid dual-eligible versus non-dual-eligible patients (AMI: 52.8 versus 60.4 percent; heart failure: 39.7 versus 49.4 percent). Differences between hospitals explained 7.3 and 7.7 percentage points of the variation in follow-up for AMI and heart failure, respectively.

"These findings indicate opportunities and challenges to equitably improving postdischarge care for all patients with AMI or heart failure," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2024-08-06 07:15

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords